Epithelial membrane protein-2 (EMP2) and experimental proliferative Vitreoretinopathy (PVR)

Current Eye Research

Volumn 36, Issue 6, 2011, Pages 546-552

  Telander, David G ^a   Morales, Shawn A ^b   Mareninov, Sergey ^c   Forward, Krisztina ^a   Gordon, Lynn K ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Epithelial membrane protein 2; Fibrosis; Integrin regulation; Proliferative vitreoretinopathy; Retina; Retinal pigment epithelium; Rhegmatogenous retinal detachment; Therapy; Vitreous membranes

Indexed keywords

EPITHELIAL MEMBRANE PROTEIN 2; EYE PROTEIN; MEMBRANE PROTEIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARPE 19 CELL LINE; ARTICLE; CELL LINE; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; PROTEIN TRANSPORT; RIBOZYME VECTOR; STABLE TRANSFECTION; VITREORETINOPATHY;

ANIMALS; CELL LINE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; PIGMENT EPITHELIUM OF EYE; RABBITS; VITREORETINOPATHY, PROLIFERATIVE;

EID: 79956262499     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.561468     Document Type: Article

References (34)

1. Pastor JC. Proliferative vitreoretinopathy: An overview. Surv Ophthalmol. 1998;43:3-18. (Pubitemid 28364465)
2. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: Risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144. (Pubitemid 34242710)
3. Colyer MH, Weber ED, Weichel ED, et al. Delayed intraocular foreign body removal without endophthalmitis during Operations Iraqi Freedom and Enduring Freedom. Ophthalmology. 2007;114:1439-1447. (Pubitemid 47126577)
4. Asaria RH, Charteris DG. Proliferative vitreoretinopathy: Developments in pathogenesis and treatment. Compr Ophthalmol Update. 2006;7:179-185. (Pubitemid 44453099)
5. Kroll P, Rodrigues EB, Hoerle S. Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica. 2007;221:78-94. (Pubitemid 46465433)
6. Morales SA, Mareninov S, Prasad P, et al. Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. Exp Eye Res. 2007;85:790-798. (Pubitemid 350166365)
7. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397-422. (Pubitemid 37487354)
8. Morales SA, Mareninov S, Wadehra M, et al. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci. 2009;50:462-469.
9. Wadehra M, Sulur GG, Braun J, et al. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol. 2003;74:106-112. (Pubitemid 36438658)
10. Forbes A, Wadehra M, Mareninov S, et al. The tetraspan protein EMP2 regulates expression of caveolin-1. J Biol Chem. 2007;282:26542-26551. (Pubitemid 47443770)
11. Wadehra M, Goodglick L, Braun J. The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol Biol Cell. 2004;15:2073-2083. (Pubitemid 38580629)
12. Wadehra M, Iyer R, Goodglick L, et al. The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion. J Biol Chem. 2002;277:41094-41100. (Pubitemid 35215700)
13. Wadehra M, Mainigi M, Morales SA, et al. Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol. 2008;6:15.
14. Wadehra M, Su H, Gordon LK, et al. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTLmediated cell death. Clin Immunol. 2003;107:129-136. (Pubitemid 36579377)
15. Wang CX, Wadehra M, Fisk BC, et al. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood. 2001;97:3890-3895.
16. Farrell HM, Jr., Jimenez-Flores R, Bleck GT, et al. Nomenclature of the proteins of cows' milk-Sixth Revision. J Dairy Sci. 2004;87:1641-1674. (Pubitemid 38893295)
17. Nakagawa M, Refojo MF, Marin JF, et al. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1995;36:2388-2395.
18. Fastenberg DM, Diddie KR, Delmage JM, et al. Intraocular injection of silicone oil for experimental proliferative vitreoretinopathy. Am J Ophthalmol. 1983;95:663-667. (Pubitemid 13092791)
19. Fastenberg DM, Diddie KR, Dorey K, et al. The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmology. 1982;93:565-572. (Pubitemid 12107405)
20. Eibl KH, Kook D, Priglinger S, et al. Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines. Invest Ophthalmol Vis Sci. 2006;47:364-370. (Pubitemid 46780837)
21. Agrawal RN, He S, Spee C, et al. In vivo models of proliferative vitreoretinopathy. Nat Protoc. 2007;2:67-77. (Pubitemid 47040070)
22. Eibl KH, Lewis GP, Betts K, et al. The effect of alkylphosphocholines on intraretinal proliferation initiated by experimental retinal detachment. Invest Ophthalmol Vis Sci. 2007;48:1305-1311. (Pubitemid 351261428)
23. Lewis GP, Sethi CS, Linberg KA, et al. Experimental retinal reattachment: A new perspective. Mol Neurobiol. 2003;28:159-175. (Pubitemid 38156430)
24. Cook B, Lewis GP, Fisher SK, et al. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1995;36:990-996.
25. Fisher SK, Erickson PA, Lewis GP, et al. Intraretinal proliferation induced by retinal detachment. Invest Ophthalmol Vis Sci. 1991;32:1739-1748.
26. Lewis GP, Chapin EA, Byun J, et al. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci. 2009;50:4429-4435.
27. Zacks DN, Zheng QD, Han Y, et al. FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2004;45:4563-4569. (Pubitemid 39564684)
28. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15:1-12. (Pubitemid 38020692)
29. Saika S, Kono-Saika S, Tanaka T, et al. Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab Invest. 2004;84:1245-1258. (Pubitemid 40063691)
30. Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye: Targets of gene therapy. Prog Retin Eye Res. 2008;27:177-196.
31. Lee H, O'Meara SJ, O'Brien C, et al. The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2007;48:4291-4299. (Pubitemid 351261061)
32. Kim IK, Arroyo JG. Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin North Am. 2002;15:81-86. (Pubitemid 34579205)
33. Harada C, Mitamura Y, Harada T. The role of cytokines and trophic factors in epiretinal membranes: Involvement of signal transduction in glial cells. Prog Retin Eye Res. 2006;25:149-164. (Pubitemid 43227842)
34. Forward KI, Yu AK, Morales SA, et al. Differential expression of epithelial membrane protein 2 in human epiretinal membranes. Invest Ophthalmol Vis Sci. 2010;51:ARVO E-abstract 6088.